Leiomyoma cells in 3-dimensional cultures demonstrate an attenuated response to fasudil, a Rho-kinase inhibitor, when compared to 2-dimensional cultures

Reproductive Sciences

Volumn 21, Issue 9, 2014, Pages 1126-1138

  Malik, Minnie ^a   Britten, Joy ^b   Segars, James ^a,b   Catherino, William H ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

2D and 3D cultures; extracellular matrix; fasudil; gel contraction; RhoA; uterine leiomyoma

Indexed keywords

COLLAGEN GEL; FASUDIL; FIBROMODULIN; FIBRONECTIN; PROCOLLAGEN; PROCOLLAGEN 1A; PROTEIN BAX; UNCLASSIFIED DRUG; VERSICAN; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; PROTEIN KINASE INHIBITOR; RHO KINASE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEIOMYOMA; MECHANOTRANSDUCTION; MYOMETRIUM; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; CULTURE TECHNIQUE; ENZYMOLOGY; FEMALE; METABOLISM; PROCEDURES; RAT; TRANSFORMED CELL LINE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE, TRANSFORMED; FEMALE; HUMANS; LEIOMYOMA; PROTEIN KINASE INHIBITORS; RATS; RHO-ASSOCIATED KINASES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 84907221175     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719114545240     Document Type: Article

References (73)

1. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.
2. Baird DD. Invited commentary: uterine leiomyomata-we know so little but could learn so much. Am J Epidemiol. 2004;159(2):113-123.
3. Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino WH. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genet. 2012;29(8):703-712.
4. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344-1355.
5. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211. e1-211.e9.
6. Eltoukhi HM, Modi MN,Weston M, Armstrong AY, Stewart EA. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014;210(3):194-199.
7. Myers ER, Barber MD, Gustilo-Ashby T, Couchman G, Matchar DB, McCrory DC. Management of uterine leiomyomata: what do we really know? Obstet Gynecol. 2002;100(1):8-17.
8. Payson M, Leppert P, Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am. 2006;33(1):1-11.
9. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med. 2010;28(3):169-179.
10. Islam MS, Protic O, Stortoni P, et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril. 2013;100(1):178-193.
11. Rogers R, Norian J, Malik M, et al. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol. 2008;198(4):e1-e11.
12. Norian JM, Owen CM, Taboas J, et al. Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma. Matrix Biol. 2012;3(1):57-65.
13. Kiss MZ, Hobson MA, Varghese T, et al. Frequency-dependent complex modulus of the uterus: preliminary results. Phys Med Biol. 2006;51(15):3683-3695.
14. Stewart EA, Taran FA, Chen J, et al. Magnetic resonance elastography of uterine leiomyomas: a feasibility study. Fertil Steril. 2011;95(1):281-284.
15. Luo T, Robinson DN. The role of the actin cytoskeleton in mechanosensation. In: Kamkin A, Kiseleva I, eds. Mechanosensitivity and Mechanotransduction, Mechanosensitivity in Cells and Tissues 4, Springer Sciences. 2011.
16. Payson M, Malik M, Siti-Nur Morris S, Segars JH, Chason R, Catherino WH. Activating transcription factor 3 gene expression suggests that tissue stress plays a role in leiomyoma development. Fertil Steril. 2008;92(2):748-755.
17. Malik M, Segars J, Catherino WH. Integrin β1 regulates leiomyoma cytoskeletal integrity and growth. Matrix Biol. 2012;31(7-8):389-397.
18. Peavey M, Salleh N, Leppert P. Collagen-binding α11 integrin expression in human myometrium and fibroids utilizing a novel RNA in situ probe [published online February 11, 2014]. Reprod Sci. 2014.
19. Van Aelst L, D'souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11(18):2295-2322.
20. Provenzano PP, Keely PJ. Mechanical signaling through the cytoskeleton regulates cell proliferation by coordinated focal adhesion and Rho GTPase signaling. J Cell Sci. 2011;124(pt 8):1195-205.
21. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer. 1999;81(5):682-687.
22. Burbelo P, Wellstein A, Pestell RG. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat. 2004;84(1):43-48.
23. Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1-2):65-76.
24. Amano M, Nakayama M, Kaibuchi K.Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010;67(9):545-554.
25. Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect. 2004;17(1):29-34.
26. Komers R. Rho kinase inhibition in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2011;20(1):77-83.
27. Komers R. Rho kinase inhibition in diabetic kidney disease. Br J Clin Pharmacol. 2013;76(4):551-559.
28. Washida N, Wakino S, Tonozuka Y, et al. Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant. 2011;26(9):2770-2779.
29. Zhou H, Zhang KX, Li YJ, Guo BY, Wang M, Wang M. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts. Clin Exp Pharmacol Physiol. 2011;38(6):387-394.
30. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci. 2012;13(7):8293-8307.
31. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93(2-3):225-232.
32. Hirooka Y, Shimokawa H. Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases. Am J Cardiovasc Drugs. 2005;5(1):31-39.
33. Fukushima M, Nakamuta M, Kohjima M, et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005;25(4):829-838.
34. Malik M, Catherino WH. Development and validation of a three-dimensional in vitro model for uterine leiomyoma and patient-matched myometrium. Fertil Steril. 2012;97(6):1287-1293.
35. Malik M, Deng J, Britten JL, Levy G, Segars J, Catherino WH. Estrogen and progesterone stimulate extracellular matrix production in myometrium and leiomyoma 3-dimensional cultures. Fertil Steril. 2013;100(3):S401.
36. Levy G, Malik M, Britten JL, Gilden M, Segars JH, Catherino WH. Liarozole inhibits transforming growth factor-Beta 3 (TGF-β3) Mediated Extracellular Matrix (ECM) formation in human 3-dimensional leiomyoma cultures. Fertil Steril. 2014;102(1):272-281.
37. Britten JL, Malik M, Levy G, Catherino WH. Early extracellular matrix protein reduction in 3-dimensional cultures treated with cetrorelix acetate compared to 2-dimensional culture systems: evidence of therapeutic efficacy. Fertil Steril. 2013;100(3):S319.
38. Malik M, Webb J, Catherino WH. Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells. Clin Endocrinol. 2008;69(3):462-470.
39. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
40. Katoh K, Kano Y, Noda Y. Rho-associated kinase-dependent contraction of stress fibers and the organization of focal adhesions. J R Soc Interface. 2011;8(56):305-311.
41. Mason BN, Califano JP, Reinhart-King CA. Matrix stiffness: a regulator of cellular behavior and tissue formation. In: Bhatia SK, ed. Engineering Biomaterials for Regenerative Medicine: Novel Technologies for Clinical Applications. Springer Science Business Media, LLC; 2012.
42. Callister WD. Fundamentals of Materials Science and Engineering: An Interactive E-Text. John Wiley & Sons, Somerset, NJ, ed. 5th Edition, 2000.
43. Discher D, Dong C, Fredberg JJ, et al. Biomechanics: cell research and applications for the next decade. Ann Biomed Eng. 2009;37(5):847-859.
44. Gilbert PM, Havenstrite KL, Magnusson KEG, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science. 2010;329(5995):1078-1081.
45. Levental I, Georges P, Janmey PA. Soft biological materials and their impact on cell function. Soft Matter. 2007;3:299-306.
46. Guan R, Xu X, Chen M, et al. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur J Med Chem. 2013;70:613-622.
47. Shiotani S, Shimada M, Suehiro T, et al. Involvement of Rho-kinase in cold ischemia-reperfusion injury after liver transplantation in rats. Transplantation. 2004;78(3):375-382.
48. Bao W, Hu E, Tao L, et al. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res. 2004;61(3):548-558.
49. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. 2010;15(15-16):622-629.
50. Bourgier C, Haydont V, Milliat F, et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut. 2005;54(3):336-343.
51. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001;69(12):1441-1453.
52. Takata M, Tanaka H, Kimura M, et al. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. 2013;170(2):341-351.
53. Chapados R, Abe K, Ihida-Stansbury K, et al. ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ Res. 2006;99(8):837-844.
54. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol. 2010;661:299-308.
55. He Y, Xu H, Liang L, et al. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappaB activation in rheumatoid arthritis. Arthritis Rheum. 2008;58(11):3366-3376.
56. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg. 1992;76(4):571-577.
57. Shibuya M, Asano T, Sasaki Y. Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir Suppl. 2001;77:201-204.
58. Raja SG. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension. Recent Pat Cardiovasc Drug Discov. 2012;7(2):100-104.
59. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420(6916):629-635.
60. Hoffman BD, Grashoff C, Schwartz MA. Dynamic molecular processes mediate cellular mechanotransduction. Nature. 2011;475(7356):316-323.
61. Leppert PC, Baginski T, Prupas C, Catherino WH, Pletcher S, Segars JH. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril. 2004;82(suppl 3):1182-1187.
62. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589-1592.
63. Malik M, Catherino WH. Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil Steril. 2007;87(5):1166-1172.
64. Norian JM, Malik M, Parker CY, et al. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153-1164.
65. Ying Z, Yue P, Xu X, et al. Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase. Am J Physiol Heart Circ Physiol. 2009;296(5):H1540-H1550.
66. Ma DW, Wang QY, Ma XY, Li J, Guan QH, Fu Y. The effect of fasudil via Rho/ROCK signaling pathway on the inflammation and fibrosis in human mesangial cells in high glucose medium. Zhonghua Nei Ke Za Zhi. 2011;50(7):580-584.
67. Taylor DK, Leppert PC. Treatment for uterine fibroids: searching for effective drug therapies. Drug Discov Today Ther Strateg. 2012;9(1):e41-e49.
68. Itoh M, Chiba H, Noutomi T, Takada E, Mizuguchi J. Cleavage of Bax-alpha and Bcl-x(L) during carboplatin-mediated apoptosis in squamous cell carcinoma cell line. Oral Oncol. 2000;36(3):277-285.
69. Wood DE, Newcomb EW. Cleavage of Bax enhances its cell death function. Exp Cell Res. 2000;256(2):375-382.
70. Toyota H, Yanase N, Yoshimoto T, Moriyama M, Sudo T, Mizuguchi J. Calpain-induced Bax-cleavage product is a more potent inducer of apoptotic cell death than wild-type Bax. Cancer Lett. 2003;189(2):221-230.
71. Thumkeo D, Watanabe S, Narumiya S. Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol. 2013;92(10-11):303-315.
72. Owen CM, Norian JM, Guo XC, Malik M, Catherino WH, Segars JH. Leiomyoma cells show attenuated mechanosensing, but increased dependence on Rho-GEF activation compared to myometrial cells. Fertil Steril. 2010;94(4):S76.
73. Fitzgibbon J, Morrison JJ, Smith TJ, O'Brien M. Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin. Reprod Biol Endocrinol. 2009;7:2.